To predict the risk of disease recurrence following definitive treatment for localized prostate cancer (PC), risk stratification tools often integrate Gleason sum (GS), prostate specific antigen (PSA), and clinical tumor (cT) stage 1, 2, 3. This evidence concerns the gene KLK3 and neoplasm.